Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Secondary Hyperparathyroidism in the Uremic Patient

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. \>18 years old~2. Secondary hyperparathyroidism; iPTH \> 350 pg/ml before any treatment or after 6 weeks without any treatment with vitamin D.~3. Chronic renal insufficiency receiving hemodialysis.~4. P-phosphate \< 1,8 mmol/l~5. P-calcium ion \< 1,25 mmol/l~6. Receiving maximal possible dose of calcium-based phosphate binder.~7. Accepting 2 x 6 weeks without vitamin D.~8. Safe anti conception in fertile women~9. Do not expect need of calcimimetics or parathyroidectomy during the next year.~10. Written informed consent.~Exclusion Criteria:~1. Malignancy~2. Disease or condition making the patient unable to participate~3. Expected lifetime less than one year.~4. Pregnancy and nursing~5. Allergic to contents of Zemplar or Etalpha~6. Currently receiving calcimimetics~7. Participating in other clinical intervention studies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): alfacalcidol 16 weeks, 6 weeks wash out, paricalcitol 16 weeks
- 2 (Type: ACTIVE_COMPARATOR): paricalcitol ´16 weeks, 6 weeks wash out, alfacalcidol 16 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).